The AVXS-101-CL-302 (Study CL-302) is also a phase 3, open-label, single-arm, single-dose study that included 33 patients with type 1 and type 2 SMA and 2 copies of SMN2. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.